Collegium Pharmaceutical Inc. Daily Stock Analysis

Daily Stock Analysis, COLL, Collegium Pharmaceutical Inc, priceseries

Collegium Pharmaceutical Inc. Daily Stock Analysis
Stock Information
Open
17.88
Close
17.42
High
17.88
Low
17.16
Previous Close
17.90
Daily Price Gain
-0.48
YTD High
22.89
YTD High Date
Feb 22, 2022
YTD Low
17.16
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.67
YTD Gain
-8.75%
52 Week High
26.17
52 Week High Date
Mar 15, 2021
52 Week Low
17.16
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-6.09
52 Week Gain
-25.90%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 1. 2017
9.17
Jun 29. 2017
11.49
20 Trading Days
25.32%
Link
LONG
Nov 9. 2017
12.71
Nov 27. 2017
15.16
11 Trading Days
19.24%
Link
LONG
Jan 10. 2018
18.91
Feb 2. 2018
22.75
16 Trading Days
20.31%
Link
LONG
Oct 2. 2018
15.34
Oct 18. 2018
17.04
12 Trading Days
11.10%
Link
LONG
Nov 20. 2018
17.15
Dec 11. 2018
18.92
13 Trading Days
10.33%
Link
LONG
Jun 19. 2019
12.09
Jul 5. 2019
12.92
11 Trading Days
6.88%
Link
LONG
Nov 1. 2019
12.85
Dec 4. 2019
20.66
22 Trading Days
60.78%
Link
LONG
May 6. 2020
19.63
May 29. 2020
21.95
16 Trading Days
11.82%
Link
LONG
Sep 28. 2020
18.78
Oct 14. 2020
21.30
12 Trading Days
13.40%
Link
LONG
Jan 6. 2021
20.59
Feb 1. 2021
23.30
17 Trading Days
13.18%
Link
LONG
Mar 8. 2021
23.51
Mar 23. 2021
24.90
11 Trading Days
5.89%
Link
LONG
Jul 15. 2021
23.52
Aug 5. 2021
24.88
15 Trading Days
5.80%
Link
Company Information
Stock Symbol
COLL
Exchange
NasdaqGS
Company URL
http://www.collegiumpharma.com
Company Phone
781-713-3699
CEO
Michael Thomas Heffernan
Headquarters
Massachusetts
Business Address
780 DEDHAM STREET, SUITE 800, CANTON, MA 02021
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001267565
About

Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through formulation based product improvements protected by intellectual property. It builds a portfolio of pain products that incorporate its patent protected DETERx formulation platform that provides for extended release and tamper resistance. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Canton, MA.

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. The company also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading